Neuralstem Receives Approval To Commence First ALS Stem Cell Trial At Emory ALS Center

Neuralstem, Inc. (NYSE Amex: CUR) announced that its Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells has been approved by the Institutional Review Board (IRB) at Emory University in Atlanta, GA. The trial, which was approved by the FDA in September, will take place at the Emory ALS Center, under the direction of Dr...
This entry was posted in News from Other Sources. Bookmark the permalink. Both comments and trackbacks are currently closed.